ArticleCurrent microbiology2025
Synergistic Antibacterial Effects of Ceftazidime/Avibactam and Auranofin Combination against Carbapenem-Resistant Klebsiella pneumoniae: In Vitro and in Vivo Evaluation.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
To investigate the antibacterial activity of ceftazidime/avibactam (CZA) combined with auranofin (AUR) against Carbapenem-resistant Klebsiella pneumoniae (CRKP) in vitro and in vivo. The minimum inhibitory concentrations (MICs) of CZA and AUR in 40 non-redundant CRKP isolates were determined by broth microdilution method. Drug resistance genes were detected by polymerase chain reaction (PCR). Checkerboard assays, time-kill assays and Galleria mellonella infection models were employed to assess the effect of CZA plus AUR in vitro and in vivo. Additionally, serial subculture experiments were used to evaluate resistance progression. 75.0% (30/40) of clinical isolates exhibited resistance to CZA. The addition of AUR resulted in a remarkable 16-fold reduction in MIC
Indexed as
Identifiers
41369993What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.